Gabric 1987

Methods	Multisite study Randomization: unclear Patients blinded; providers blinded
Participants	Geographic region: Croatia Study setting: community N = 30 Baseline IPSS: NA Baseline prostate volume: NA Mean age: 65.0 Age range: 40 to 82 Race: White Diagnostic criteria: BPH, stage I–II (Vahlensieck)
Interventions	Control: placebo Treatment: Prostagutt® forte (Serenoa repens and Urtica dioica) 20 drops thrice daily Study duration: 6 weeks Lost to follow up: none
Outcomes	Physician rating of improvement Peak urine flow Bladder residual volume Dropouts due to side effects: none
Notes	Exclusions: Stage IV prostate adenoma; bacterial prostatitis; cystitis; urethritis
Risk of bias
Item	Authors’ judgement	Description
Adequate sequence generation?	Unclear	B
Allocation concealment?	Unclear	B
Blinding? All outcomes	Yes	A - Adequate
Incomplete outcome data addressed? All outcomes	Unclear	B
Free of selective reporting?	Unclear	A - Adequate
Free of other bias?	Unclear	A - Adequate